Cardiac rehabilitation for Congenital Heart Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Congenital Heart Disease+1 MoreCardiac rehabilitation - Behavioral
Eligibility
18 - 60
All Sexes
What conditions do you have?
Select

Study Summary

This trial will look at whether an exercise program can help improve brain function in adults with congenital heart disease.

Eligible Conditions
  • Congenital Heart Disease
  • Congenital Heart Defects

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Baseline, post-intervention at 3 months

Month 3
Change in brain hemodynamics
Changes in cardiac hemodynamic
Changes in cardiorespiratory fitness
Changes in episodic memory
Changes in executive functions
Changes in general cognitive functioning
Changes in processing speed

Trial Safety

Trial Design

2 Treatment Groups

Control
1 of 2
Intervention
1 of 2

Active Control

Experimental Treatment

100 Total Participants · 2 Treatment Groups

Primary Treatment: Cardiac rehabilitation · No Placebo Group · N/A

Intervention
Behavioral
Experimental Group · 1 Intervention: Cardiac rehabilitation · Intervention Types: Behavioral
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cardiac rehabilitation
2006
Completed Phase 3
~740

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, post-intervention at 3 months

Who is running the clinical trial?

Montreal Heart InstituteLead Sponsor
114 Previous Clinical Trials
63,201 Total Patients Enrolled
Louis Bherer, PhDPrincipal InvestigatorEPIC Center of the Montreal Heart Institute
8 Previous Clinical Trials
841 Total Patients Enrolled

Eligibility Criteria

Age 18 - 60 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a diagnosis of congenital heart disease with moderate or severe risk.
References